Logo

Hikma Entered into an Exclusive License Agreement with Celltrion for Yuflyma (biosimilar, adalimumab)

Share this
Hikma Entered into an Exclusive License Agreement with Celltrion for Yuflyma (biosimilar, adalimumab)

Hikma Entered into an Exclusive License Agreement with Celltrion for Yuflyma (biosimilar, adalimumab)

Shots:

  • Hikma gets exclusive rights to commercialize Yuflyma, the first proposed high concentration, low-volume & citrate-free adalimumab biosimilar in MENA markets
  • The agreement will strengthen Hikma’s offering of biosimilar & biologic products with the addition of Yuflyma to its portfolio. Celltrion’s capabilities & well-established commercial presence continue to increase patient's access to vital medications that aid in their battle against challenging diseases
  • Hikma has launched three of Celltrion’s biosimilar products i.e., Truxima, Remsima & Herzuma. A fourth product, Remsima SC, an infliximab formulation is currently being developed & will be available soon

Ref: Hikma | Image: Hikma 

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions